New partnership: Xilaplus® AF in Turkey
Noventure is delighted to announce its new partnership with Generica İlaç to market Noventure’s Xilaplus® AF in Turkey.
Allergy Asthma Clin Immunol. 2017 Aug 10;13:37 Full text free!!
Abstract:
Background:
To evaluate barrier protective properties of Rhinosectan® spray, a medical device containing xyloglucan, on nasal epithelial cells (MucilAir).
Following the publication of the experimental study by Fraile B et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018
We are pleased to announce the launch of Tasectan® Duo in Austria by our partner company Montavit. This will be Duo´s second market, after the successful introduction in Italy by Angelini.
Future Microbiol. 2017 Oct 25.
Abstract:
Aim:
To compare the protective efficacy of gelatine tannate/probiotic with other antidiarrheal agents in Escherichia coli-inoculated CacoGoblet® cells.
NOVENTURE will be present at the FNM 2018 Annual Meeting to be held in Amsterdam, 29 August – 1 September
Expert Opin Investig Drugs. 2017 Dec 26:1-6.
We are pleased to announce the launch in Israel of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is distributed by our long term partner Lapidot.
We are pleased to announce the launch in France of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is commercialized over the French territory under the umbrella brand Cysticare / Utipro plus and is distributed by Vemedia, our partner for the product in the Netherlands as well.